Flotetuzumab clinical trials
Also written MGD006 and RES234.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses flotetuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 6
City of Hope Medical Center (2) · Children's Oncology Group (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Washington University School of Medicine (1) · MacroGenics (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1)
Studies
Open first, then newest update. How each study uses flotetuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid LeukemiaActive, not recruitingPhase 1Children's Oncology GroupNCT04158739Written as Flotetuzumab
- Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological MalignanciesCompletedPhase 1City of Hope Medical CenterNCT04681105Written as Flotetuzumab
- Post-transplant Flotetuzumab for AMLCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05506956Written as Flotetuzumab
- Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)TerminatedPhase 2Washington University School of MedicineNCT04582864Written as Flotetuzumab
- Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)TerminatedPhase 1/2MacroGenicsNCT02152956Written as Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
- Study to Assess an Interphase Cycle With Flotetuzumab.WithdrawnPhase 2Stichting Hemato-Oncologie voor Volwassenen NederlandNCT05063123Written as Flotetuzumab
- Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerWithdrawnPhase 2City of Hope Medical CenterNCT03739606Written as Anti-CD123/CD3 Monoclonal Antibody MGD006
Codes
What other systems call flotetuzumab · ClinicalTrials.gg INT014185
- UNII (FDA) 0AHT0IC02GFLOTETUZUMABConfirmed FDA, Wikidata
- Wikidata Q55639724flotetuzumabConfirmed FDA, Wikidata
- NCI Thesaurus C117238FlotetuzumabOne source FDA
- DrugBank DB15223One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0AHT0IC02G | FLOTETUZUMAB | Confirmed FDA, Wikidata |
| Wikidata | Q55639724 | flotetuzumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C117238 | Flotetuzumab | One source FDA |
| DrugBank | DB15223 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.